Status:
TERMINATED
Alfuzosin for Voiding Dysfunction in Multiple Sclerosis (MS)
Lead Sponsor:
Nova Scotia Health Authority
Collaborating Sponsors:
Sanofi
Conditions:
Multiple Sclerosis
Bladder Dysfunction
Eligibility:
All Genders
18+ years
Phase:
PHASE2
PHASE3
Brief Summary
Multiple Sclerosis is often associated with severe functional deficits resulting in a range of progressive impairments. Approximately 80% of patients have bladder symptoms at the time of diagnosis and...
Detailed Description
OBJECTIVE The primary objective of this study is to evaluate the use of Alfuzosin in the treatment of bladder dysfunction in patients with Multiple Sclerosis (MS). STUDY POPULATION Twenty (20) partic...
Eligibility Criteria
Inclusion
- Participant should be eighteen years of age or older.
- Participant should have LUTS secondary to Multiple Sclerosis as defined below.
- Participant should have frequency ≥ 8/day and/or incontinence and/or nocturia ≥ 2/night and/or urgency and/or urinary retention.
- Participant should be able to understand, speak and read English.
- Participant 's urine culture should not show any evidence of urinary tract infection.
- Participant should be willing to take part in the study and sign the consent form.
- Female participants consents to use a medically acceptable method of birth control throughout the entire study period and for four weeks after the study is completed. Medically acceptable methods of contraception that may be used by the study participants and/or their partner includes abstinence, birth control pills or patches, diaphragm with spermicide, IUD, condom and vaginal spermicide, surgical sterilization, vasectomy, progestin implants or injections.
Exclusion
- Participant with known hypersensitivity to Alfuzosin.
- Participant with history of postural hypotension and/or syncope.
- Participant has used another alpha blocker within the last 30 days.
- Participant has active urethral stricture disease.
- Participant has a history of prostate cancer within the preceding five years.
- Participant has hepatic dysfunction.
- Participant has renal dysfunction.
- Participant has unstable angina pectoris.
- Participant has a positive pregnancy test at the time of screening.
- Participant has a history of serious social, mental or medical conditions that would stop patient from taking part in the study.
- Participant has a history of alcohol or drug abuse within the last five years.
- Participant who is currently being treated for chronic bacterial prostatitis or painful bladder syndrome/interstitial cystitis.
- Participant has a significant medical problem which the investigator considers a serious risk for the patient to be part of the study.
- Use of any investigational drug or device within the last 6 months.
- Participant who is unwilling or unable to abide by the requirements of study.
- Participant has a bladder infection proven by urine culture.
Key Trial Info
Start Date :
November 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
November 1 2009
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT00688948
Start Date
November 1 2007
End Date
November 1 2009
Last Update
June 27 2011
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
QE II Health Science Centre, Halifax Infirmary
Halifax, Nova Scotia, Canada, B3H 3A7